Subscribe
Home
Issues
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
2021 Year in Review - Multiple Myeloma
2021 Year in Review: Advances in Dual IO Cancer Treatments
2021 Year in Review - Breast Cancer
2021 Oncology Drug Coding and Updates
2021 Year in Review - Renal-Cell Carcinoma
2021 Year in Review - Ovarian Cancer
2021 Year in Review - Gastrointestinal Cancer
2021 Year in Review - Non–Small-Cell Lung Cancer
2021 Year in Review - Biosimilars
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2021 Novel Oncology Drug Approvals
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
ASH 2021 - AML
ASH 2021 - Myelofibrosis
2021 Myelofibrosis Wrap-Up
AACR & ASCO 2021 - Midyear Review
ASCO 2021 - Lung Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes
Special Issues
2021 Oncology Drug Coding and Updates
2021 Oncology Drug Coding and Updates
A Valuable Resource for Oncology Practices
By
Dawn Holcombe, MBA, FACMPE, ACHE
We are pleased to present this 2021 Oncology Drug Coding and Updates special feature, designed to provide you with helpful information on the topic of oncology drug coding and important details on some of the drugs now available to treat patients with cancer. The COVID-19 pandemic led to many changes in patient care and treatment choices for oncology practices. Flexibility and innovation regarding both oral and infused/injected drugs became key to ensuring patient access to necessary treatments.
Read More ›
Drugs Frequently Used in the Treatment of Cancer and Their Associated Codes and Pricing
The following tables of frequently used oncology drugs are intended to assist practice managers, other healthcare providers, and payers in the proper use of coding and billing information associated with the treatment of their patients.
Read More ›
Zejula (Niraparib) First PARP Inhibitor Approved for First-Line Maintenance Therapy in All Women with Advanced Ovarian Cancer, Regardless of Biomarker Status
By
Loretta Fala
Drug Updates
Ovarian cancer—including epithelial cancer, fallopian tube cancer, and primary peritoneal cancer—often affects women aged 55 to 64 years, with nearly 70% of all cases occurring in women aged ≥45 years. In 2020, an estimated 21,750 women will be newly diagnosed with ovarian cancer, and approximately 13,940 women will die from this disease in the United States.
Read More ›
Tabrecta (Capmatinib) Approved for Patients with Metastatic NSCLC and MET Exon 14 Skipping Mutation
By
Loretta Fala
Drug Updates
Lung and bronchus cancer is the second most prevalent form of cancer in the United States.
1
Representing 12.7% of all new cancer cases, lung cancer was diagnosed in 228,820 individuals in 2020. It is the leading cause of cancer-related mortality in men and women, accounting for 22.4% of all cancer deaths.
Read More ›
Tazverik (Tazemetostat) First FDA-Approved Treatment Specifically for Patients with Epithelioid Sarcoma
By
Loretta Fala
Drug Updates
Epithelioid sarcoma is a rare subtype of soft-tissue sarcoma that most often occurs in the soft tissue of the fingers, hands, and forearms, but that can occur in other areas of the body. In 2005 in the United States, the incidence of epithelioid sarcoma was approximately 0.04 cases per 100,000 people. Epithelioid sarcoma predominantly affects young adults; however, it can affect individuals at any age and is more prevalent in males than in females. Characterized by slow tumor growth and benign manifestations at early stages, epithelioid sarcoma can be challenging to diagnose.
Read More ›
View the Latest Issue of OPM
Read Issue
Top Trending Articles
1.
2022 Midyear Review: Non–Small-Cell Lung Cancer
2.
New Policies Regarding Intravenous Iron Replacement Are Creating Conundrum for Providers and Payers
By
Dawn Holcombe, MBA, FACMPE, ACHE
3.
Oncology Guide to Patient Support Services Index
Home
Issues
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
2021 Year in Review - Multiple Myeloma
2021 Year in Review: Advances in Dual IO Cancer Treatments
2021 Year in Review - Breast Cancer
2021 Oncology Drug Coding and Updates
2021 Year in Review - Renal-Cell Carcinoma
2021 Year in Review - Ovarian Cancer
2021 Year in Review - Gastrointestinal Cancer
2021 Year in Review - Non–Small-Cell Lung Cancer
2021 Year in Review - Biosimilars
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2021 Novel Oncology Drug Approvals
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
ASH 2021 - AML
ASH 2021 - Myelofibrosis
2021 Myelofibrosis Wrap-Up
AACR & ASCO 2021 - Midyear Review
ASCO 2021 - Lung Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes
Subscribe Today!
To sign up for our newsletter or print publications, please enter your contact information below.
I'd like to receive:
OPM
Print Edition
OPM
Weekly e‑Newsletter
Afghanistan
Åland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia, Plurinational State of
Bonaire, Sint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Congo, the Democratic Republic of the
Cook Islands
Costa Rica
Côte d'Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic of
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People's Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia, the former Yugoslav Republic of
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory, Occupied
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Russian Federation
Rwanda
Saint Barthélemy
Saint Helena, Ascension and Tristan da Cunha
Saint Kitts and Nevis
Saint Lucia
Saint Martin (French part)
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Sint Maarten (Dutch part)
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan, Province of China
Tajikistan
Tanzania, United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela, Bolivarian Republic of
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
I have reviewed and consent to the terms of
OPM
's
Privacy Policy
, and
OPM
has my permission to retain my information in its database, and to forward pertinent communications to me.
START YOUR SUBSCRIPTION